lsd1/kdm1a

DDP-38003 dihydrochloride is an orally available histone lysine-specific demethylase 1A (KDM1A LSD1) inhibitor (IC50: 84 nM).

TAK-418 is a selective and orally active inhibitor of LSD1 KDM1A enzyme with an IC50 of 2.9 nM. TAK-418 unlocks abnormal epigenetic mechanisms and improves autism symptoms in models of neurodevelopmental disorders.

Pulrodemstat HCl is an orally active, selective and potent lysine demethylase-1 (LSD1) inhibitor, and a selective KDM1A inhibitor, with anticancer and anti-proliferative activities, inhibiting HNSCC cell proliferation and migration Inhibits the growth of head and neck squamous cell carcinoma by triggering apoptosis.

ORY1001 (ORY 1001) is an orally active and selective lysine-specific demethylase LSD1 KDM1A inhibitor, with high selectivity against related FAD dependent aminoxidases with IC50 of <20 nM.

Seclidemstat (SP-2577) is an effective LSD1 inhibitor, with a mean IC50 of 127 nM.

DDP-38003 trihydrochloride is a novel, orally available histone lysine-specific demethylase 1A (KDM1A LSD1) inhibitor with an IC50 of 84 nM.

Iadademstat dihydrochloride (ORY-1001(trans)) , a Potent and Selective Covalent KDM1A LSD1 Inhibitor, for the Treatment of Acute Leukemia.

Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC50 of 13 nM. It shows promising potential in enhancing antitumor immunity in switch sucrose nonfermentable (SWI SNF) complex mutated ovarian cancer and exhibits inhibitory effects on virus production, viral DNA replication, and late gene expression. Additionally, seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings.

FY-56, a highly potent and selective inhibitor of LSD1 KDM1A with an IC50 value of 42 nM, demonstrates significant selectivity over MAO-A B. This compound effectively induces differentiation in MOLM-13 and MV4-11 cells, showing promise for acute myeloid leukemia (AML) research [1].